TY - JOUR
T1 - Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents
T2 - A Systematic Review and Meta-Analysis of Clinical Trials
AU - Keshavarzian, Ehsan
AU - Sadighpour, Tella
AU - Mortazavizadeh, Seyed Mohammadreza
AU - Soltani, Mohammadhossein
AU - Motevalipoor, Amir Farzin
AU - Khamas, Shahriyar Shahbazi
AU - Moazen, Mohammad
AU - Kogani, Mohammad
AU - Amin Hashemipour, Seyed Mohammad
AU - Hosseinpour, Hamid
AU - Valizadeh, Rohollah
N1 - Publisher Copyright: © 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - BACKGROUND: Anthracyclines can improve survival in many types of malignancies, but dose-dependent and irreversible results following the use of anthracyclines have been associated with cardiomyopathy. This meta-analysis aimed to compare the effects of prophylactic agents for preventing cardiotoxicity induced following anticancer agents.METHODS: In this meta-analysis, Scopus, Web of Science, and PubMed were surfed for articles published by December 30 th, 2020. The keywords were angiotensin-converting enzyme inhibitor (ACEI), enalapril, captopril, angiotensin receptor blocker, beta blocker, metoprolol, bisoprolol, isoprolol, statin, valsartan, losartan, eplerenone, idarubicin, nebivolol, dihydromyricetin, ampelopsin, spironolactone, dexrazoxane, antioxidants, cardiotoxicity, n-acetyl-tryptamine, cancer, neoplasms, chemotherapy, anthracyclines, doxorubicin, daunorubicin, epirubicin, idarubicin, ejection fraction or a combination of them in the titles or abstracts. RESULTS: A total of 17 articles out of 728 studies examining 2,674 patients were included in this systematic review and meta-analysis. Ejection fraction (EF) values in the baseline, 6-month, and 12-month follow-up in the intervention group turned out to be 62.52 ± 2.48, 59.63 ± 4.85, and 59.42 ± 4.53, whereas in the control group appeared to be 62.81 ± 2.58, 57.69 ± 4.32, and 58.60 ± 4.58, respectively. Through comparison of the two groups, EF was found to increase in the intervention group by 0.40 after 6 months (Standardized mean difference (SMD): 0.40, 95% confidence interval (CI): 0.27, 0.54), thus proving higher than that of the control groups following the cardiac drugs.CONCLUSION: This meta-analysis showed that prophylactic treatment with cardio-protective drugs, including dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with anthracycline, have a protective effect on LVEF and prevent EF drop.
AB - BACKGROUND: Anthracyclines can improve survival in many types of malignancies, but dose-dependent and irreversible results following the use of anthracyclines have been associated with cardiomyopathy. This meta-analysis aimed to compare the effects of prophylactic agents for preventing cardiotoxicity induced following anticancer agents.METHODS: In this meta-analysis, Scopus, Web of Science, and PubMed were surfed for articles published by December 30 th, 2020. The keywords were angiotensin-converting enzyme inhibitor (ACEI), enalapril, captopril, angiotensin receptor blocker, beta blocker, metoprolol, bisoprolol, isoprolol, statin, valsartan, losartan, eplerenone, idarubicin, nebivolol, dihydromyricetin, ampelopsin, spironolactone, dexrazoxane, antioxidants, cardiotoxicity, n-acetyl-tryptamine, cancer, neoplasms, chemotherapy, anthracyclines, doxorubicin, daunorubicin, epirubicin, idarubicin, ejection fraction or a combination of them in the titles or abstracts. RESULTS: A total of 17 articles out of 728 studies examining 2,674 patients were included in this systematic review and meta-analysis. Ejection fraction (EF) values in the baseline, 6-month, and 12-month follow-up in the intervention group turned out to be 62.52 ± 2.48, 59.63 ± 4.85, and 59.42 ± 4.53, whereas in the control group appeared to be 62.81 ± 2.58, 57.69 ± 4.32, and 58.60 ± 4.58, respectively. Through comparison of the two groups, EF was found to increase in the intervention group by 0.40 after 6 months (Standardized mean difference (SMD): 0.40, 95% confidence interval (CI): 0.27, 0.54), thus proving higher than that of the control groups following the cardiac drugs.CONCLUSION: This meta-analysis showed that prophylactic treatment with cardio-protective drugs, including dexrazoxane, beta blocker, and ACEI drugs in patients undergoing chemotherapy with anthracycline, have a protective effect on LVEF and prevent EF drop.
KW - ACE inhibitor
KW - anthracyclines
KW - beta blocker
KW - cancer
KW - ejection fraction
KW - prophylactic agents
UR - http://www.scopus.com/inward/record.url?scp=85160458907&partnerID=8YFLogxK
U2 - https://doi.org/10.2174/1574887118666230118102252
DO - https://doi.org/10.2174/1574887118666230118102252
M3 - Article
C2 - 36803186
SN - 1574-8871
VL - 18
SP - 112
EP - 122
JO - Reviews on recent clinical trials
JF - Reviews on recent clinical trials
IS - 2
ER -